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a b s t r a c t
We report the ﬁrst case of acute myeloid leukemia (AML) with RUNX1–MECOM fusion transcripts,
showing marked eosinophilia. A 63-year old man admitted in August 2013, had previously been
observed in April 2013, because of persisting homogeneous splenomegaly and increased LDH, which
were initially attributed to both minor β-thalassemia and previous acute myocardial infarction. However,
based upon the retrospective analysis of clinical features combined with the documentation of both JAK2
V617F and c-KIT D816V mutations at AML diagnosis, an aggressive leukemic transformation with
eosinophilia of a previously unrecognized myeloproliferative neoplasm, rather than the occurrence of de
novo AML, may be hypothesized.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
The t(3;21)(q26;q22) is a rare cytogenetic abnormality, reported
in approximately 1% of all myelodysplastic syndrome (MDS) or acute
myeloid leukemia (AML) cases and mainly occurring in therapy-
related myeloid neoplasms, in accelerated or blast phase of chronic
myeloid leukemia or other myeloproliferative neoplasms (MPN), and,
rarely, in de novo AML [1–6]. Previous treatment with hydroxycarba-
mide or other antimetabolites is strongly implicated as a contributory
cause [4]. The presence of t(3;21)(q26;q22), isolated or associated
with other chromosomal abnormalities, is associated with a very
poor prognosis [5]. In this translocation, portions of the RUNX1 gene
have been reported to be variably fused to MECOM (currently
preferred designation for the genes located within the 3q26 region,
namely RPL22, MDS1, EVI1), as a result of alternative intergenic
splicing, with production of multiple fusion transcripts [1–3].
RUNX1–MECOM (formerly AML1–MDS1–EVI1) fusion products
directly contribute to leukemogenesis or leukemic transformation,
can block myeloid differentiation and promote proliferation by
exerting a dominant-negative effect over RUNX1-induced normal
transcriptional activation, antagonize the growth-inhibitory effects of
transforming growth factors, block JNK activity and therefore prev-
ent stress-induced apoptosis, and enhance AP-1 activity [7,8]. We
report here the unusual case of an elderly patient observed because
of persisting splenomegaly and increased lactate dehydrogenase
(LDH), heralding AML with eosinophilia and RUNX1–MECOM fusion
transcripts.
In details, a 63-year old Caucasian man with previous history of
minor β-thalassemia, arterial hypertension, hypothyroidism, ﬁbro-
myalgia, benign prostatic hyperplasia and acute myocardial infarction
in 2009 was admitted to our outpatient's Hematology Unit in April
2013 because of splenomegaly and persistently increased LDH,
mainly LDH2 isoform, since 2009. The blood examinations docu-
mented white blood cell (WBC) count 4.7109/L, with a differential
count showing 47% neutrophils, 34% lymphocytes, 9% monocytes, 5%
eosinophils, 5% basophils, hemoglobin (Hb) level 15.4 g/dl with MCV
76 ﬂ, platelet (Plt) count 338109/L, serum LDH 1053 IU/L. The
morphological examination of the peripheral blood (PB) smear did
not document cytological abnormalities, while neutrophil alkaline
phosphatase activity was elevated. Neither abnormal myeloid cells
nor atypical lymphocytes were detected by ﬂow cytometry on PB
samples. Microbiological, virological and autoimmunity examinations
were negative. Homogeneous splenomegaly (bipolar diameter
16.2 cm) without signs of portal hypertension was observed on
ultrasonography. Neither bone marrow (BM) examination nor cyto-
genetic and molecular analyses were performed at this time-point,
whereas the morphological examination of a BM aspirate performed
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in 2008 because of transient mild neutropenia was unrevealing. In
August 2013 the patient was subsequently admitted because of fever,
fatigue, abdominal pain and drenching night sweats. The laboratory
investigations revealed WBC count 12.2109/L with a differential
count showing 25% neutrophils, 11% lymphocytes, 2% monocytes,
43% eosinophils, 1% basophils and 18% blasts, Hb level 9.7 g/dl, Plt
count 17109/L, LDH 548 IU/L. Unfortunately, serum tryptase level
was not measured. Homogeneous splenomegaly was worsened
(bipolar diameter 20 cm), as observed on abdominal ultrasonogra-
phy. The morphological examination of BM aspirate (Fig. 1A) and
trephine biopsy (Fig. 1B) showed hypercellularity (90%), with marked
proliferation of eosinophil granulocytopoiesis (40%), multilineage
myelodysplastic features, especially with small hypolobated mega-
karyocytes, and a blast cell count 20–30%. Blast cells were minimally
differentiated, with high nuclear/cytoplasmic ratio and basophilic
cytoplasm. They were CD34þ , CD33þ/ , CD13þ , CD117þ , HLA-
DRþ , CD38þ , c-MPO by ﬂow cytometry analysis performed on
the BM aspirate. Moreover, mild BM ﬁbrosis was documented on
Gomori methenamine silver staining (Fig. 1C). The presence of dense
mast cell collections or atypical spindle-shaped mast cells was
morphologically excluded. Moreover, neither immunohistochemical
examinations for CD68 and CD117 nor ﬂow-cytometry analyses to
investigate the expression of CD2, CD25 and CD117, performed on
BM trephine biopsy and BM aspirate, respectively, documented
atypical or aggregated mast cells (not shown). Unfortunately, immu-
nostaining for tryptase was not performed. Based upon these
features, AML with MDS-related changes and eosinophilia was thus
diagnosed. Conventional G-banding showed 46,XY,t(3;21)(q26;q22)
karyotype in all the 20 metaphase cells analyzed (Fig. 1D). Molecular
examinations, namely reverse transcriptase (RT)-PCR (Fig. 1E) and
subsequent sequencing analyses (Fig. 1F) performed on both PB and
BM samples, also documented RUNX1–MECOM, alternatively spliced
multiple fusion transcripts [1–3].
Further extensive FISH and molecular studies failed to detect
either BCR–ABL, PDGFRA, PDGFRB and FGFR1 rearrangements or
NPM1 and FLT3 mutations, whereas c-KIT D816V mutation was
found on PB and BM mononuclear cells. Moreover, allele-speciﬁc
PCR demonstrated JAK2 V617F mutation on both PB and BM
polymorphonuclear cells, but JAK2 V617F allele burden was not
assessed at AML diagnosis or during the subsequent course of
the disease. An aggressive clinical behavior was observed. The
patient was refractory to remission induction chemotherapy
(cytarabine 100 mg/m2 on days 1–7 and daunorubicin 45 mg/
m2 on days 1–3) and subsequent salvage chemotherapeutic FLAG
regimen (ﬂudarabine 30 mg/m2 and cytarabine 2 g/m2 on days
1–5, G-CSF, 5 mcg/kg/day from day 1 to day þ5). Thereafter, he
received best supportive care and was lost of follow-up.
To the best of our knowledge, we have described here the ﬁrst
case of AML with RUNX1–MECOM fusion transcripts and concur-
rent JAK2 V617F and c-KIT D816V mutations, showing marked
peripheral and BM eosinophilia. AML with eosinophilia is usually
found in core binding factor (CBF) leukemias, with cytogenetic
abnormalities such as inv(16)(p13q22)/t(16;16)(p13;q22) resulting
in CBFB–MYH11 fusion transcript or t(8;21)(q22;q22) resulting in
RUNX1–RUNX1T1 fusion transcript. However, it is also rarely
associated with other translocations such as t(16;21)(q24;q22),
which produces the RUNX1–CBFA2T3 fusion transcript [9].
Of interest, c-KIT mutations are documented in approximately
25–30% of cases of CBF leukemia, whereas they are infrequent in
other AML subtypes [10]. It has also recently been reported that
patients with t(8;21)-positive AML showed one or two additional
gene mutations in up to 50% or 15% of the cases, respectively [11].
The most common mutated genes, in that series, were c-KIT
(23/139 patients; 16.5%), NRAS (18/139 patients; 12.9%) and ASXL1
(16/139 patients; 11.5%), but also FLT3, CBL, KRAS, IDH2 and JAK2
were mutated in 2.9–5% of the cases [11]. Of note, our patient was
Fig. 1. (A–F) Morphological examination of bone marrow (BM) aspirate, showing minimally differentiated myeloid blasts (arrow) and abnormal eosinophil precursors
(arrowhead), concurrently with small hypolobated megakaryocytes (*) (A, May Grunwald Giemsa, magniﬁcation 400 ). BM trephine biopsy, showing hypercellularity with
marked proliferation of eosinophil granulocytopoiesis, a blast cell count 20–30% (B, hematoxylin–eosin, magniﬁcation 200 ) and mild BM ﬁbrosis (C, Gomori methenamine
silver staining, magniﬁcation 100 ). Conventional G-banding showing 46,XY,t(3;21)(q26;q22) karyotype (D). Reverse-transcriptase PCR (E) conﬁrmed the presence of
RUNX1–MECOM fusion transcripts. Alternatively spliced multiple fusion transcripts including RUNX1–RPL22 (316 bp, lane 4), RUNX1–MDS1 (328 bp, lane 9) and RUNX1–
MDS1–EVI1 (861 and 669 bp, lane 14) products were detected. Lanes 1–3, lanes 6–8 and lanes 11–13 refer to negative controls. Lanes 5 and 10 refer to molecular weight
marker VIII. Subsequent sequencing analyses conﬁrmed breakpoints of RUNX1–MECOM fusion transcripts. Diagrammatic representation of RUNX1–MDS1 fusion product
with detailed sequencing results at the fusion junction site is shown (F).
F. Forghieri et al. / Leukemia Research Reports 3 (2014) 83–8584
previously observed, a few months before AML diagnosis, because
of persisting homogeneous splenomegaly and increased LDH,
which, in the absence of any other features suspected for hema-
tologic malignancy, except for a mild increase of morphologi-
cally normal basophils, were initially attributed to both minor
β-thalassemia and previous acute myocardial infarction. However,
based upon the retrospective analysis of the clinical features
combined with the documentation of both JAK2 V617F and c-KIT
D816V mutations on PB and BM samples at AML diagnosis, an
aggressive leukemic transformation with eosinophilia and t(3;21)
(q26;q22) translocation of a previously unrecognized MPN, rather
than the occurrence of a de novo AML, may be hypothesized in our
case [4,5]. Unfortunately, PB samples adequate for molecular
examinations were not stored in April 2013, so we could not
retrospectively investigate the presence of JAK2 and KIT mutations
at ﬁrst patient's observation. In the absence of available samples
for BM morphological examinations or cytogenetic/molecular
analyses before AML diagnosis, we cannot have conﬁrmation of a
potential MPN diagnosis preceding AML. Furthermore, neither
JAK2 V617F allele burden at different time-points nor JAK2
V617F mutation analysis on puriﬁed myeloid blasts were available,
so that we cannot exclude that such mutation would have been
limited to polymorphonuclear cells. Of note, the latter possibility
would not be surprising, because it has previously been reported
that leukemic blasts are frequently negative for the JAK2 V617F
mutation in transformed JAK2 V617F-positive MPN [12]. The
unusual clinical picture of our patient may suggest the need to
perform either BM morphological examinations or cytogenetic/
molecular analyses, at least on PB samples, to rule out MPN in
similar cases observed for persisting/worsening splenomegaly and
increased LDH, even in the absence of signiﬁcant morphological
and immunophenotypic abnormalities on PB. Furthermore, we
have reported the association of AML with eosinophilia with
another chromosomal translocation involving RUNX1, located at
21q22 region, suggesting the need to further investigate molecular
mechanisms underlying the presence of abnormal eosinophilia in
hematologic malignancies.
Conﬂict of interest
The authors indicated no potential conﬂicts of interest.
Authors' contributions
FF and SB analyzed clinical, cytogenetic and molecular data and
wrote the manuscript; MM, LP, VF, LF, VN, AM, AP took care of the
patient, collected and analyzed clinical data and critically revised
the manuscript; ML critically revised the manuscript. All authors
approved the ﬁnal version of the manuscript.
FF and SB equally contributed to the work.
Acknowledgments
This work was supported by grants from the Associazione
Italiana Lotta alle Leucemie, Linfoma e Mieloma (AIL) – Sezione
‘Luciano Pavarotti’ Modena-ONLUS (to FF and LP) and from the
Associazione Italiana per la Ricerca sul Cancro (AIRC, IG 14797-
2013 to ML).
References
[1] Nucifora G, Begy CR, Kobayashi H, Roulston D, Claxton D, Pedersen-Bjergaard J,
et al. Consistent intergenic splicing and production of multiple transcripts
between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22)
translocations. Proc Natl Acad Sci USA 1994;91:4004–8.
[2] Park TS, Choi JR, Yoon , Song J, Kim J, Kim SJ, et al. Acute promyelocytic
leukemia relapsing as secondary acute myelogenous leukemia with transloca-
tion t(3;21)(q26;q22) and RUNX1–MDS1–EVI1 fusion transcript. Cancer Genet
Cytogenet 2008;187:61–79.
[3] Yang JJ, Cho SY, Suh JT, Lee HJ, Lee WI, Yoon HJ, et al. Detection of RUNX1-
MECOM fusion gene and t(3;21) in a very elderly patient having acute myeloid
leukemia with myelodysplasia-related changes. Ann Lab Med 2012;32:362–5.
[4] Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D. t(3;21)(q26;q22) in
myeloid leukemia: an aggressive syndrome of blast transformation associated
with hydroxyurea or antimetabolite therapy. Cancer 2006;106:1730–8.
[5] Li SL, Yin CC, Medeiros J, Bueso-Ramos C, Lu GL, Lin P. Myelodysplastic
syndrome/acute myeloid leukemia with t(3;21)(q26.2;q22) is commonly a
therapy-related disease associated with poor outcome. Am J Clin Pathol
2012;138:146–52.
[6] Mitelman F, Johansson B, Mertens F., editors. Mitelman Database of Chromo-
some Aberrations and Gene Fusions in Cancer. Available at 〈http://cgap.nci.nih.
gov/Chromosomes/Mitelman〉; 2013 [accessed 27.12.13].
[7] Lo Coco F, Pisegna S, Diverio D. The AML1 gene: a transcription factor involved
in the pathogenesis of myeloid and lymphoid leukemias. Haematologica
1997;82:364–70.
[8] Mitani K. Molecular mechanisms of leukemogenesis by AML1/EVI-1. Onco-
gene 2004;23:4263–9.
[9] Park IJ, Park JE, Kim HJ, Jung HJ, Lee WG, Cho SR. Acute myeloid leukemia with
t(16;21)(q24;q22) and eosinophilia: case report and review of the literature.
Cancer Genet Cytogenet 2010;196:105–8.
[10] Paschka P, Dohner K. Core-binding factor acute myeloid leukemia: can we
improve on HiDAC consolidation? Hematol Am Soc Hematol Educ Program
2013:209–19.
[11] Krauth MT, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, et al. High
number of additional genetic lesions in acute myeloid leukemia with t(8;21)/
RUNX1–RUNX1T1: frequency and impact on clinical outcome. Leukemia
2014;28:1449–58.
[12] Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, et al.
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders
are frequently negative for the JAK2-V617F mutation. Blood 2007;110:375–9.
F. Forghieri et al. / Leukemia Research Reports 3 (2014) 83–85 85
